UBS Group
IRD

UBS Group’s Opus Genetics IRD Stock Holding History

UBS Group’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.17M Buy
257,649
+167,831
+187% +$581K ﹤0.01% 5432
2025
Q4 		$181K Buy
89,818
+88,934
+10,060% +$181K ﹤0.01% 6633
2025
Q3 		$1.46K Sell
884
-27,226
-97% -$33.8K ﹤0.01% 9344
2025
Q2 		$26.5K Sell
28,110
-11,854
-30% -$11K ﹤0.01% 8254
2025
Q1 		$39.2K Buy
39,964
+7,273
+22% +$8.13K ﹤0.01% 7761
2024
Q4 		$38.9K Buy
32,691
+27,004
+475% +$31K ﹤0.01% 7462
2024
Q3 		$7.45K Sell
5,687
-10,016
-64% -$15.4K ﹤0.01% 7907
2024
Q2 		$24K Buy
15,703
+1,475
+10% +$2.55K ﹤0.01% 7185
2024
Q1 		$28.6K Buy
14,228
+8,830
+164% +$22.4K ﹤0.01% 6759
2023
Q4 		$16.2K Buy
+5,398
New +$16K ﹤0.01% 7229
2023
Q3 		– Sell
-8,751
Closed -$38K – 10070
2023
Q2 		$38K Buy
8,751
+8,187
+1,452% +$38.9K ﹤0.01% 6614
2023
Q1 		$2.12K Buy
+564
New +$2.02K ﹤0.01% 8576
2022
Q4 		– Sell
-1,700
Closed -$3K – 11236
2022
Q3 		$3K Sell
1,700
-766
-31% -$1.65K ﹤0.01% 9603
2022
Q2 		$5K Sell
2,466
-3,282
-57% -$7.46K ﹤0.01% 8951
2022
Q1 		$19K Sell
5,748
-1,397
-20% -$4.78K ﹤0.01% 7529
2021
Q4 		$27K Sell
7,145
-693
-9% -$2.78K ﹤0.01% 7511
2021
Q3 		$41K Buy
7,838
+2,296
+41% +$10.6K ﹤0.01% 6509
2021
Q2 		$30K Buy
5,542
+3,732
+206% +$18.5K ﹤0.01% 6948
2021
Q1 		$11K Buy
+1,810
New +$16.8K ﹤0.01% 7876
2020
Q3 		– Sell
-272
Closed -$3K – 8483
2020
Q2 		$3K Sell
272
-679
-71% -$6.24K ﹤0.01% 7566
2020
Q1 		$7K Sell
951
-634
-40% -$5.51K ﹤0.01% 7170
2019
Q4 		$12K Buy
1,585
+176
+12% +$1.33K ﹤0.01% 7199
2019
Q3 		$12K Buy
1,409
+1,367
+3,255% +$19K ﹤0.01% 7066
2019
Q2 		$1K Sell
42
-600
-93% -$13.6K ﹤0.01% 7751
2019
Q1 		$16K Buy
642
+340
+113% +$11.3K ﹤0.01% 6509
2018
Q4 		$14K Buy
302
+145
+92% +$8.47K ﹤0.01% 7053
2018
Q3 		$13K Buy
157
+105
+202% +$8.11K ﹤0.01% 7043
2018
Q2 		$4K Sell
52
-100
-66% -$8.79K ﹤0.01% 7571
2018
Q1 		$11K Buy
152
+132
+660% +$12K ﹤0.01% 6820
2017
Q4 		$2K Buy
+20
New +$2.03K ﹤0.01% 7636
2017
Q3 		– Sell
-1
Closed – – 8052
2017
Q2 		$0 Buy
+1
New +$194 ﹤0.01% 8047
2017
Q1 		– Sell
-62
Closed -$4K – 8047
2016
Q4 		$4K Sell
62
-63
-50% -$5.13K ﹤0.01% 7341
2016
Q3 		$13K Sell
125
-98
-44% -$11.8K ﹤0.01% 6617
2016
Q2 		$27K Buy
223
+202
+962% +$28.3K ﹤0.01% 6047
2016
Q1 		$3K Hold
21
– – ﹤0.01% 7214
2015
Q4 		$4K Sell
21
-2
-9% -$425 ﹤0.01% 7797
2015
Q3 		$6K Sell
23
-35
-60% -$9.51K ﹤0.01% 7623
2015
Q2 		$17K Sell
58
-8
-12% -$2.72K ﹤0.01% 7032
2015
Q1 		$23K Sell
66
-45
-41% -$16.3K ﹤0.01% 6862
2014
Q4 		$37K Buy
+111
New +$38.3K ﹤0.01% 6867

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

UBS Group's IRD Position: Q1 2026 in Review

UBS Group increased its Opus Genetics (IRD) stake by 187% in Q1 2026, buying an estimated $581K and bringing the position to 257,649 shares worth $1.17M. The position accounts for ﹤0.01% of the portfolio, ranked #5432.

UBS Group first reported a position in IRD in Q4 2014 and has held it in 40 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • UBS Group held 257,649 shares of Opus Genetics worth $1.17M as of Q1 2026.
  • UBS Group bought 167,831 Opus Genetics shares in Q1 2026, an estimated $581K.
  • Opus Genetics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #5432 holding.
  • UBS Group first reported a position in Opus Genetics in Q4 2014 and has held it in 40 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.